Other Events ·
LifeMD, Inc. entered into a strategic co-marketing collaboration with Antares Pharma, Inc., a subsidiary of Halozyme…
LFMDLifeMD, Inc.
LifeMD, Inc. entered into a strategic co-marketing collaboration with Antares Pharma, Inc., a subsidiary of Halozyme, Inc., to support a direct-to-patient self-pay program for XYOSTED® (testosterone enanthate) injection. The program, launching in July 2026, will be available in 37 states and will utilize the Company's telehealth and pharmacy services to evaluate and prescribe, dispense, and ship XYOSTED directly to patients' homes. The agreements have an initial term of three years with automatic one-year renewals. LifeMD, Inc. is a telehealth and pharmacy services provider in the healthcare industry.